Immunotherapy has emerged as one of the most significant advances in modern oncology, offering new hope to patients whose cancers were once considered difficult to treat. By harnessing the body’s own immune system, this approach targets cancer cells in ways that traditional treatments often cannot.
Key Takeaways
- Immunotherapy works by activating or enhancing the immune system to recognize and destroy cancer cells.
- Several cancer types — including melanoma, lung cancer, and bladder cancer — show strong responses to immunotherapy.
- Not all cancers respond equally; tumor biology, mutation burden, and immune markers influence treatment outcomes.
- Multiple forms of immunotherapy exist, including checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines.
- Oncologists use biomarker testing to determine whether a patient is likely to benefit from immunotherapy.
What Types of Cancer Can be Treated with Immunotherapy?
A wide range of malignancies can be addressed using immunotherapy cancer treatment options, though eligibility depends on the specific cancer type, stage, and individual patient factors. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) have approved immunotherapy drugs for dozens of indications across multiple cancer categories. According to the National Cancer Institute, approvals now cover cancers of the lung, skin, kidney, bladder, liver, colon, cervix, and several blood-related malignancies, among others.
Blood cancers were among the earliest beneficiaries of immune-based strategies. Leukemia, lymphoma, and multiple myeloma have all been targets of approved immunotherapies, particularly chimeric antigen receptor T-cell (CAR-T) therapy. Solid tumors followed, with checkpoint inhibitors proving especially effective in melanoma and non-small cell lung cancer (NSCLC). The expanding list of approvals reflects both the versatility of the approach and the growing body of clinical evidence supporting its use.
The table below provides an overview of key cancer types for which immunotherapy has received regulatory approval, along with representative treatment categories.
| Cancer Type | Immunotherapy Category | Example Agents |
|---|---|---|
| Melanoma | Checkpoint inhibitors | Pembrolizumab, Ipilimumab |
| Non-Small Cell Lung Cancer | Checkpoint inhibitors | Nivolumab, Atezolizumab |
| Bladder Cancer | Checkpoint inhibitors | Avelumab, Pembrolizumab |
| Renal Cell Carcinoma | Checkpoint inhibitors, cytokines | Nivolumab, Interleukin-2 |
| Acute Lymphoblastic Leukemia | CAR-T cell therapy | Tisagenlecleucel |
| Hodgkin Lymphoma | Checkpoint inhibitors | Pembrolizumab, Nivolumab |
| Head and Neck Cancers | Checkpoint inhibitors | Pembrolizumab, Nivolumab |
| Colorectal Cancer (MSI-H) | Checkpoint inhibitors | Pembrolizumab |
How Immunotherapy Works Differently Across Cancer Types
The immune system interacts with tumors in highly variable ways depending on the cancer’s origin, genetic makeup, and microenvironment. Immunotherapy for different types of cancer therefore does not follow a single universal protocol; instead, treatment is tailored to exploit specific vulnerabilities present in each tumor type. Checkpoint inhibitors, for example, work by blocking proteins such as PD-1, PD-L1, or CTLA-4 that cancer cells use to evade immune detection. Once these “brakes” are released, T-cells can mount a more effective attack against the tumor.
CAR-T cell therapy takes a different approach. It involves collecting a patient’s own T-cells, genetically engineering them to recognize specific proteins on cancer cells, and infusing them back into the body. This method has shown remarkable results in certain blood cancers, where tumor cells express consistent surface markers that the engineered T-cells can reliably target. In contrast, many solid tumors present a more heterogeneous surface profile, making this approach more complex to apply.
Cancer vaccines represent another mechanism. Therapeutic vaccines, unlike preventive ones, are designed to treat existing cancers by training the immune system to recognize and eliminate tumor cells. Sipuleucel-T, approved for advanced prostate cancer, was among the first therapeutic cancer vaccines to gain FDA approval. Additionally, monoclonal antibodies can be engineered to attach directly to cancer cells and flag them for immune destruction or deliver toxic payloads directly to tumor sites. Each mechanism reflects a distinct strategy for leveraging immune biology against malignancy.
Cancers That Respond Best to Immunotherapy
Research consistently identifies certain malignancies as particularly responsive to immune-based strategies. Melanoma was the first solid tumor to demonstrate dramatic, durable responses to checkpoint inhibitors. Clinical trials showed that a subset of patients with advanced melanoma achieved long-term remission — an outcome that had been extremely rare with conventional chemotherapy. The FDA approval of ipilimumab in 2011 marked a turning point for the field and validated immunotherapy as a frontline treatment option.
NSCLC has since become one of the most studied contexts for checkpoint inhibitor use. Patients whose tumors express high levels of PD-L1 tend to respond more favorably, and immunotherapy has been approved both as a standalone treatment and in combination with chemotherapy for this indication. According to the American Cancer Society, lung cancer remains the leading cause of cancer-related death in the United States, making effective new options critically important for patients and clinicians alike.
Renal cell carcinoma, Hodgkin lymphoma, and bladder cancer also fall among the cancers treated with immunotherapy with well-documented response rates. Tumors with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) — a molecular characteristic found across multiple cancer types including colorectal, endometrial, and gastric cancers — have shown particularly strong responses to pembrolizumab. This led the FDA to grant a tumor-agnostic approval, meaning eligibility is based on a molecular marker rather than the organ of origin, which was a landmark shift in how oncologists think about cancer treatment classification.
The following factors are associated with stronger immunotherapy responses across cancer types:
- High tumor mutational burden (TMB-H), which generates more neoantigens for immune recognition
- High PD-L1 expression on tumor cells
- MSI-H or dMMR status
- Active immune cell infiltration within the tumor microenvironment
- Absence of certain resistance mechanisms, such as loss of MHC-I expression
Is Immunotherapy Used for All Cancers?
Immunotherapy is not a universal solution. While the range of types of cancer immunotherapy can treat continues to grow, some cancers remain largely unresponsive to currently available immune-based treatments. Pancreatic cancer, for instance, is notorious for creating an immunosuppressive tumor microenvironment that shields it from immune attack. Similarly, most forms of brain cancer, including glioblastoma, have shown limited benefit from checkpoint inhibitors in large clinical trials, despite significant research investment.
Several factors determine whether a patient is a suitable candidate. Oncologists typically order biomarker testing before initiating treatment, evaluating markers such as PD-L1 expression, tumor mutational burden, and MSI status. These tests help predict which patients are likely to derive meaningful benefit and which may experience toxicity without a corresponding clinical gain. Immune-related adverse events — side effects caused by an overactivated immune system — can affect the lungs, liver, intestines, and endocrine glands, and may be severe in some individuals.
Even within a single cancer type, not every patient responds the same way. Two individuals with the same diagnosis may have very different tumor biology, leading to divergent outcomes under identical treatment regimens. This variability underscores the importance of personalized medicine and ongoing research into combination strategies that pair immunotherapy with chemotherapy, targeted therapy, or radiation to overcome resistance and broaden eligibility. Clinical trials continue to evaluate new agents and combinations that may extend the reach of immunotherapy to cancers that currently lack effective options.
Frequently Asked Questions
Can immunotherapy be combined with other cancer treatments?
Yes. Oncologists frequently combine immunotherapy with chemotherapy, radiation, or targeted therapies to improve outcomes. Combinations can enhance immune activation, reduce tumor burden before immunotherapy begins, or overcome resistance mechanisms. For example, pembrolizumab combined with chemotherapy is a standard first-line option for certain lung cancers. The appropriateness of combination therapy depends on cancer type, stage, and individual patient health, and is determined through comprehensive oncological evaluation.
How do doctors determine if a patient qualifies for immunotherapy?
Eligibility is assessed through biomarker testing of tumor tissue or blood samples. Key markers include PD-L1 expression levels, tumor mutational burden, and MSI or dMMR status. Pathology reports, imaging results, and overall patient health also factor into the decision. Because some markers predict both response and risk of serious side effects, thorough evaluation is essential before treatment begins. Multidisciplinary tumor boards often review complex cases to guide treatment planning.
Are the side effects of immunotherapy different from those of chemotherapy?
Yes, the side effect profiles differ significantly. Chemotherapy primarily damages rapidly dividing cells, causing hair loss, nausea, and bone marrow suppression. Immunotherapy, by contrast, activates the immune system broadly, which can lead to immune-related adverse events affecting the skin, lungs, liver, colon, or hormone-producing glands. These effects can range from mild rashes to serious inflammation requiring corticosteroid treatment. Recognizing and managing these events early is critical to maintaining patient safety during immunotherapy.
